News

Medical Marijuana, Inc. Major Investment AXIM Biotech Enters Clinical Study Agreement with University of British Columbia to Begin Clinical Trial On CBD Chewing Gum For Treatment of Drug-Related Psychosis

August 3, 2017

general-hemp-blog-medical-cannabis-17-01-10-ver1

SAN DIEGO, Aug. 3, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM) has entered into a Clinical Study Agreement (CSA) with

Medical Marijuana, Inc Major Investment AXIM Biotech Enters Agreement With Israel-Based CRO To Begin Clinical POC Study For Treatment Of Restless Leg Syndrome

July 27, 2017

general-hemp-blog-images-11-16-16-ver1

SAN DIEGO, July 27, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that its major investment AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM) has entered into a Services Agreement with an Israel-based contract research organization (CRO)

AXIM Biotech Enters Services Agreement With Israel-Based CRO to Begin Clinical POC Study on CBD and Gabapentin Chewing Gum for Treatment of Restless Leg Syndrome

July 21, 2017

general-hemp-blog-images-11-16-16-ver1

AXIM Biotechnologies, Inc. (AXIM Biotech) AXIM, +2.42% a world leader in cannabinoid research and development, today announced that it has entered into a Services Agreement with an Israel-based contract research organization (CRO) to begin a clinical proof of concept study (POC) with its cannabidiol

Reuters Features Medical Marijuana, Inc.’s Major Investment Company AXIM Biotech In Article Citing Company’s Development Of Marijuana-Based Painkiller To Combat Opioid Crisis

June 27, 2017

general-hemp-blog-medical-cannabis-17-01-10-ver1

NEW YORK, June 27, 2017 — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM), a world leader in cannabinoid research and

SeeThruEquity Initiates Coverage On Medical Marijuana, Inc. Investment Company AXIM Biotech (OTC: AXIM) With A Target Price Of $17.00

May 17, 2017

iStock_000028679138_Small

SAN DIEGO, May 17, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC PINK:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM) received coverage initiation from SeeThruEquity, a

AXIM Biotech Clinical Study to Develop Bioequivalent Product to Marinol Listed on Clinicaltrials.gov

May 16, 2017

general-hemp-blog-medical-cannabis-17-01-10-ver1

NEW YORK, May 15, 2017 –– AXIM® Biotechnologies, Inc. (AXIM® Biotech) AXIM, +37.64% a world leader in cannabinoid research and development, today announced that information on the company’s Bioavailability Study on Dronabinol in a controlled-release, functional chewing gum form is now

Medical Marijuana, Inc. Major Investment AXIM Biotech Moves Forward With Development Of MedChew Rx Pharmaceutical Chewing Gum

May 3, 2017

general-hemp-blog-medical-cannabis-17-01-10-ver1

SAN DIEGO, May 3, 2017 — Medical Marijuana, Inc. (MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc.’s (AXIM® Biotech) (AXIM) product development partner Quay Pharmaceuticals Ltd. (“Quay

Medical Marijuana, Inc. Major Investment AXIM Biotech Enters Term Sheet Agreement With U.S. API Company To Develop Bioequivalent Product To Marinol

March 28, 2017

general-hemp-blog-medical-cannabis-17-01-10-ver1

SAN DIEGO, March 28, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTCQB:AXIM), has entered into a Term Sheet Agreement with a U.S.-based controlled-substances API

Medical Marijuana, Inc. Investment AXIM Biotech Retains Ora To Manage Upcoming Product Development And Clinical Trials On Glaucoma And Dry Eye Indications

March 21, 2017

general-hemp-blog-images-11-16-16-ver1

NEW YORK, March 21, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM®Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, has

Medical Marijuana, Inc. Investment AXIM® Biotech Announces Enrolled Patients Begin Phase II Trial For The Treatment Of Irritable Bowel Syndrome (IBS) With CanChew Plus® Cannabidiol (CBD) Chewing Gum

March 7, 2017

general-hemp-blog-images-11-16-16-ver1

NEW YORK, March 7, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM) has enrolled 40 patients and commenced its Phase